Researchers are gaining a clearer understanding of how colorectal cancer manipulates the body’s immune defenses, specifically by altering the behavior of monocytes – a type of white blood cell. A new study details how these monocytes, when exposed to patient-derived cancer cells grown in a lab, adopt characteristics resembling those found in tumors themselves, potentially hindering the immune system’s ability to fight the disease. This research, focused on tumor-associated macrophages, offers a novel platform for studying the complex interplay between cancer cells and the immune system, and could pave the way for more effective therapies.
The study, published in December 2025 in Mol Biomed, centers on the behavior of monocytes in the tumor microenvironment. Tumor-associated macrophages (TAMs), derived from these monocytes, are known to play a dual role in cancer progression – sometimes promoting tumor growth, and other times contributing to anti-tumor immunity. Though, the precise signals that dictate which path they take have remained largely elusive. Understanding these cues is critical for developing strategies to reprogram these cells to fight cancer rather than fuel it.
Mimicking the Tumor Environment in the Lab
To investigate this, researchers created a unique in vitro system. They co-cultured primary human monocytes – monocytes directly obtained from human donors – with patient-derived organoids (PDOs). These organoids are three-dimensional, miniature versions of tumors grown from patient samples, offering a more realistic model of the tumor microenvironment than traditional two-dimensional cell cultures. The researchers focused on organoids derived from patients with microsatellite-stable colorectal cancer, a common subtype of the disease.
What they discovered was striking. Monocytes exposed to the PDOs underwent significant changes, distinct from those induced by standard laboratory methods used to “polarize” monocytes into different functional states. Using single-cell RNA sequencing, a powerful technique that analyzes the gene expression of individual cells, the team found that these PDO-exposed monocytes closely resembled monocytes programmed by IL1B – a signaling molecule previously identified in the tumor tissues of colorectal cancer patients. This suggests that the tumor cells are actively instructing the monocytes to adopt a pro-tumor phenotype.
A Shift in Monocyte Function
The researchers delved deeper into the mechanisms driving this transformation. They found that soluble factors released by the PDOs triggered the production of chemokines – signaling proteins that attract immune cells – specifically CXCL2, CXCL5, and CXCL7. These chemokines could contribute to the recruitment of other immune cells to the tumor site, potentially creating an environment that favors tumor growth.
the study revealed that when monocytes engulfed debris from the tumor cells, their ability to present antigens – fragments of the tumor that would normally alert the immune system – was impaired. This disruption of antigen presentation effectively cloaks the tumor from immune detection. The researchers similarly observed that the PDO-exposed monocytes exhibited a reduced capacity to mount an inflammatory response when stimulated with TLR (Toll-like receptor) agonists, further suggesting a suppression of their anti-tumor activity. A related study published in January 2024 in J Transl Med also highlighted the role of monocyte-derived TAMs in promoting tumor development in colorectal cancer.
Implications for Future Therapies
The researchers emphasize that their in vitro co-culture system provides a valuable platform for dissecting the complex interactions between cancer cells and monocytes. It allows for a more nuanced understanding of myeloid plasticity – the ability of monocytes to change their function – and its role in cancer progression. This knowledge could be crucial for developing targeted therapies that reprogram these cells to enhance anti-tumor immunity.
“This research highlights the importance of considering the tumor microenvironment when developing cancer treatments,” explains Wan Tang, the lead author of the study published in Mol Biomed. “By understanding how cancer cells manipulate immune cells like monocytes, People can design strategies to overcome these mechanisms and restore the immune system’s ability to fight the disease.”
The Dual Nature of TAMs
The findings underscore the complex and often contradictory roles of tumor-associated macrophages (TAMs). Although some TAMs can directly kill cancer cells, others promote tumor growth by suppressing the immune response and fostering angiogenesis – the formation of new blood vessels that feed the tumor. The challenge lies in identifying ways to selectively target the pro-tumor TAMs while preserving the beneficial anti-tumor activity of other immune cells.
The study’s focus on microsatellite-stable colorectal cancer is also significant. This subtype of the disease, which accounts for a substantial proportion of cases, is often less responsive to immunotherapy than microsatellite-instable tumors. Understanding the mechanisms by which these tumors evade the immune system is therefore critical for developing new treatment strategies.
Researchers will continue to refine these in vitro models and explore potential therapeutic interventions. The next steps will involve testing whether drugs that block the production of CXCL2, CXCL5, and CXCL7, or that enhance antigen presentation, can restore the anti-tumor activity of monocytes in the lab and, in patients with colorectal cancer.
This research offers a promising avenue for improving outcomes for patients battling this challenging disease. If you or someone you know is affected by colorectal cancer, resources and support are available through organizations like the American Cancer Society and the Crohn’s & Colitis Foundation.
Share this article to help raise awareness about the latest advancements in colorectal cancer research and the importance of understanding the complex interplay between cancer and the immune system.
